HCW Biologics Inc. announced that Dr. Hing C. Wong, its Founder and CEO, will serve as a panelist at the 2025 GenScript Biotech Global Forum on January 15, 2025. The forum, held alongside the J.P. Morgan Healthcare Conference, focuses on conquering Cell and Gene Therapy (CGT) challenges in biomanufacturing and supply chain management.
Dr. Wong is scheduled to discuss how HCWB's proprietary molecules, constructed with its new drug discovery platform, could potentially benefit CGT by significantly reducing costs. He will also address how these molecules could improve the clinical efficacy of engineered effector cells for CGT.
Additionally, Dr. Wong will present his perspective on why Immune-Cell Engagers, including those created by HCW Biologics, could effectively challenge cell-based therapies as optimal treatments for cancer, autoimmune diseases, and aging-related indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.